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ABSTRACT: Gaucher disease is caused by inherited deficiency 
in glucocerebrosidase (GBA, a retaining E-glucosidase), and defi-
ciency in GBA constitutes the largest known genetic risk factor for 
3DUNLQVRQ¶VGLVHDVH,QWKHSDVWDQLPDOPRGHOVRI*DXFKHUGLVHDVH
have been generated by treatment with the mechanism-based GBA 
inhibitors, conduritol B epoxide (CBE) and cyclophellitol. Both 
compounds however also target other retaining glycosidases, ren-
dering generation and interpretation of such chemical knockout 
models complicated. Here we demonstrate that cyclophellitol de-
rivatives carrying a bulky hydrophobic substituent at C8 are potent 
and selective GBA inhibitors and that an unambiguous Gaucher an-
imal model can be readily generated by treatment of zebrafish with 
these. 
Glucocerebrosidase (acid glucosylceramidase, GBA, E.C. 
3.2.1.45,) is a lysosomal retaining E-glucosidase that belongs to the 
glycoside hydrolase (GH) 30 (www.cazy.org)1 family and degrades 
the glycosphingolipid, glucosylceramide through a two-step Ko-
shland double displacement mechanism (Figure 1a). Inherited de-
ficiency in GBA causes the most common autosomal recessive ly-
sosomal storage disorder, Gaucher disease.2 Individuals carrying 
heterozygous mutations in the gene coding for GBA do not develop 
Gaucher disease but have a remarkable increased risk for develop-
ing 3DUNLQVRQ¶VGLVHDVH(PD) and Lewy-body dementia.3±5 Appro-
priate animal models linking impaired GBA functioning to Gau-
FKHUGLVHDVHDQG3DUNLQVRQ¶VGLVHDVHDUHLPSHUDWLYHERWKIRUXQder-
standing the pathophysiology of these diseases and for the devel-
opment of effective treatments for these. Since complete genetic 
abrogation of GBA hampers animal viability due to skin permea-
bility problems,6 research models have been generated in the past 
in a chemical knockdown strategy by making use of the mecha-
nism-based, covalent and irreversible retaining E-glucosidase in-
hibitor, conduritol B epoxide (CBE, 1, Figure 1b) or its close struc-
tural analogue, cyclophellitol (2, Figure 1b).7,8 One complication in 
the use of these compounds is their relative lack of selectivity.9 We 
found that cyclophellitol 2 is unsuited for creating a reliable Gau-
cher animal model because it targets GBA and GBA2 with about 
equal efficiency.9 On the other hand, CBE 1 exhibits some GBA 
selectivity but it also inhibits lysosomal D-glucosidase (GAA),10±13 
non-lysosomal glucosylceramidase (GBA2),14,15 and lysosomal Ʌ-
glucuronidase (GUSB)16. Effective mouse models can be generated 
with CBE 1 but the therapeutic window is rather narrow and varies 
in cellular and animal models.  
Recent research from our group has revealed that functionalized 
cyclophellitol derivatives carrying a BODIPY substituent at C8 
(cyclophellitol numbering ± the primary carbon corresponding to 
C6 in glucose) are very potent and very selective activity-based 
probes (ABPs) for monitoring GBA activity in vitro, in situ and in 
vivo.17,18 The presence of a bulky and hydrophobic substituent at 
this position at once proved beneficial for GBA inactivation (ABPs 
3 and 4 (Figure 1c,d) proved to inhibit GBA in the nanomolar 
range, whereas cyclophellitol 2 is a high nanomolar to micromolar 
GBA inactivator) and detrimental to inhibition of other retaining E-
glucosidases. Following these studies, Vocadlo and co-workers de-
signed a set of fluorogenic substrates featuring a fluorophore at C6 
of a E-glucoside the aglycon of which carried a fluorescence 
quencher; compounds that proved to be very selective GBA sub-
strates in situ.19 These results altogether evoked the question 
whether cyclophellitols bearing a simple, hydrophobic moiety at 
C8, such as compounds 6 and 7 (Figure 1d), would be suitable com-
pounds for generating chemical knockdown Gaucher animal mod-
els. We here show the validity of this reasoning in the generation 
of a GBA-deficient Dario rerio zebrafish model, as revealed by the 
accumulation of elevated levels of the Gaucher harbinger lysolipid, 
glucosylsphingosine, using cyclophellitol derivatives 6 and 7. 
At the onset of our studies, we sought for structural support for 
the design of compounds 6 and 7. We have in the recent past syn-
thesized Cy5-functionalized cyclophellitol 5 (unpublished) and ob-
tained a crystal structure of human recombinant GBA soaked with 
this ABP (reported here). As expected (Figure 2a), the active site 
nucleophile (in both molecules of the asymmetric unit) had reacted 
with the epoxide to yield the covalently bound cyclitol in 4C1-con-
formation, with the Cy5 moiety, via its flexible linker, clearly 
bound in one molecule of the asymmetric unit (the differences may 
reflect crystal packing constraints in a soaking experiment) accom-
modated by a hydrophobic pocket in GBA. Previous studies by us 
on the bacterial glycoside hydrolase, Thermoanaerobacterium xy-
lanolyticum Tx*+ȕ-glucosidase, a close homologue of human 
GBA2 with a conserved active site, instead showed DQ³LQZDUGV´
position of O6 (SI Figure 2a)  and a narrower and less hydrophobic 
pocket (SI Figure 2b) which may partially mitigate against the 
binding of O6-functionaised probes, thus allowing sufficient dis-
crimination for GBA over GBA2.20,21 
 Figure 1. a) Glucocerebrosidase (GBA) hydrolyses glucosylceramide in a two-step double displacement mechanism to yield glucose and 
ceramide. b) Chemical structure of CBE 1 and cyclophellitol 2. c) Mechanism-based inactivation of GBA by glucopyranoside-configured 
cyclitol epoxides (shown for cyclophellitol). d) Structures of C8-extended cyclophellitol derivatives used in the here-presented studies: GBA 
activity-based probes ABPs 3-5 and selective inhibitors 6 and 7 (see for the full chemical structures of ABPs 3-5 and 8-14 the Supporting 
Information). 
 
Biphenyl-cyclophellitol 6 and adamantyl-cyclophellitol 7 were 
synthesized following adaptations of literature cyclophellitol syn-
theses (see Supporting Information for synthesis details of Cy5-cy-
clophellitol ABP 5 and compounds 6 and 7) to generate superior 
selective GBA inhibitors for the generation of a Gaucher model 
zebrafish.22,23 
Figure 2. Structure of GBA reacted with ABP 5 and adamantyl-
cyclophellitol 7. a) GBA dimer, with the cyclophellitol and linker 
moiety of 5 shaded in yellow, and a single observed Cy5 in pink. 
b) Zoomed view of a GBA monomer reacted with ABP 5. c) Struc-
ture of GBA with adamantyl-cyclophellitol 7. The linker-adaman-
tyl moiety of 7 is observed in slightly different positions in the two 
molecules of the asymmetric unit (PDB Code 6Q6L, Figure S2) 
reflecting its binding through predominantly hydrophobic interac-
tions. 
Although soaking of GBA crystals with 6 did not yield suitable 
structures for structural analysis (Figure S2), soaking with 7 did 
(Figure 2c), and again revealed binding of the hydrophobic moiety 
(here, the adamantane) to the same hydrophobic cavity and pocket 
occupied by the O6 linker on Cy5 ABP 5. Several hydrophobic res-
idues, including Tyr313, Phe246, and Trp348 provide the wide cav-
ity that is able to accommodate different hydrophobic O6 substitu-
ents which is absent in RWKHUKXPDQȕ-glucosidases and which pro-
vides the structural basis for the inhibitory (and substrate) prefer-
ences of GBA. 
We evaluated the in vitro activity and selectivity of compounds 6 
and 7 towards GBA and the two major off-target glycosidases of 
CBE 1, GBA2 and GAA, by pre-incubating the inhibitors with re-
combinant human GBA (rGBA, Cerezyme), human GBA2 (from 
lysates of GBA2 overexpressed cells), and recombinant human 
GAA (rGAA, Myozyme) for 3 h, followed by enzymatic activity 
measurement. We showed that both compound 6 and 7 were nano-
molar inhibitors of rGBA (apparent IC50 values = 1.0 nM), which 
were 4,000-fold more potent than CBE 1 (apparent IC50 values = 
4.28 µM) (Figure 3a, S3) with improved lipophilic ligand efficien-
cies (LipE) (Table S2). Both compounds 6 and 7 were rather inac-
tive towards GBA2 and GAA (apparent IC50 values > 100 µM), 
similar to ABP 3 and 5 (Figure 3a, S4). When comparing their se-
lectivity towards GBA, both compounds 6 and 7 exhibited IC50 ra-
tio (GBA2/GBA and GAA/GBA) of > 100,000, thus making them 
4,000-times and 200-times more selective than CBE 1 (IC50 ratio = 
23.6 for GBA2/GBA and 444 for GAA/GBA) (Figure 3a). To eval-
uate the in vivo activity of compound 6 and 7, compounds were 
added to the egg-water containing zebrafish (Danio rerio) embryos, 
and incubated for 5 days at 28 °C before subsequent homogeniza-
tion and enzyme selectivity analysis by appropriate ABP labeling. 
9,24
 Quantification of ABP-labeled bands revealed that compounds 
6 and 7 had in vivo apparent IC50 values towards GBA of 4 to 6 nM, 
and that they were 5- to 70- fold more potent than ABP 3 or 5 and 
7,500 fold more potent than CBE 1 (Figure 3b, S5) in the zebrafish 
larvae. More importantly, an improved selective inactivation of  
 Figure 3. a) Apparent IC50 values for in vitro inhibition of GBA, 
GBA2 and GAA in recombinant enzymes (rGBA and rGAA) or 
overexpressed cell lysates (GBA2) by compounds 1, 2, 3, 5, 6 and 
7. Error ranges depict standard deviations from biological tripli-
cates. b) Apparent IC50 values for in vivo inhibition in 5-day treated 
zebrafish embryo with compounds 1, 2, 3, 5, 6 and 7. Error ranges 
depict standard deviations from n = 12 to 24 individuals. c) Com-
petitive ABPP in lysates of zebrafish treated in vivo with com-
pounds 6 and 7 using broad-spectrum retaining E-glucosidase ABP 
8 and selective GBA ABP 5 as read-out. d) Glucosylsphingosine 
levels produced in zebrafish embryos treated for five days with in-
hibitors 6, 7 or CBE 1.9 Error ranges depict standard deviations 
from n = 3 individuals. N/A, not analyzed. *, p < 0.5; ***, p < 
0.001. 
GBA was achieved with both compounds 6 and 7. At a concentra-
tion of 0.1-10 µM of compound 6 or 7, ABP labeling of GBA with 
broad-spectrum retaining ȕ-glucosidase ABP 8 (Figure S1) and 
GBA specific ABP 5 was abrogated (Figure 3c), while other en-
zymes such as GBA2, LPH (Figure 3c) or GAA, ER Į-glucosidase 
GANAB, and lysosomal ȕ-glucuronidase GUSB (Figure S6a, S6b) 
were not affected. 
At 0.1-10 µM of inhibitor 6 or 7, we also observed 10- to 30-fold 
elevation in the level of glucosylsphingosine (GlcSph), which is 
known to be formed by acid ceramidase-mediated conversion of 
accumulating GlcCer in lysosomes.25,26 Therefore, this observation 
also strongly points to in vivo inactivation of lysosomal GBA. For 
comparison, reaching similar GlcSph levels in the zebrafish with 
CBE required 1,000 to 10,000-fold higher concentration in com-
parison with compounds 6 or 7 (Figure 3d), concentrations at which 
GBA2 and GAA may also be targeted (Figure 3b). Finally, we in-
vestigated the brain permeability of these new inhibitors - a crucial 
feature for their future application in the study of neuropathic Gau-
FKHUGLVHDVHDQG3DUNLQVRQ¶VGLVHDVH Adult zebrafish of 3 PRQWKV¶ 
age were treated with DMSO, ABP 3 or compound 7 (1,6 
QPROILVKDSSUR[LPDWHO\ȝPRONJ administrated via food intake, 
and after 16 h brains and other organs were isolated, homogenized, 
and analyzed by ABP labeling using ABP 5 (GBA), ABP 8 (GBA2 
+ GBA), ABP 11 (GAA at pH 4.0 and ER Į-glucosidase GANAB 
at pH 7.0), and ABP 13 (lysosomal ȕ-glucuronidase GUSB) (Fig-
ure S1). Labeling of brain homogenate of adult zebrafish with ABP 
5 resulted in considerable GBA labeling in control and ABP 3-
treated fish, but no labeling in brain homogenates from fish treated 
with compound 7 (Figure 4). Labeling by the broad-spectrum ȕ-
glucosidase ABP 8 showed that GBA2 was not a target of com-
pound 7, nor was the lower running band (48 kDa), which we hy-
pothesize to be the cytosolic ȕ-glucosidase, GBA3. We noted that 
the expression level of this protein is likely variable among indi-
vidual fish, as 4 out of 6 fishes in the control group lacked this band. 
In the visceral organs (both liver and spleen), both ABP 3 and com-
pound 7 selectively abrogated GBA, while not affecting the label-
ing on other tested glycosidases (Figure S7). 
Figure 4. In vivo targets of ABP 3 and 7 in brains of adult zebrafish. 
Competitive ABPP in adult zebrafish homogenates with selective 
GBA ABP 5 (a) or broad-spectrum retaining E-glucosidase ABP 8 
(b) as read-out. 
To summarize, crystallographic studies aided the rational design 
of novel cyclophellitol analogues 6 and 7, which turned out to be 
very potent and selective GBA inhibitors, also in zebrafish embryos 
 and adult zebrafish (GBA2/GBA inhibition ratio > 1,000). Com-
pound 7, that also completely block GBA activity in the brain, is in 
our opinion superior to CBE 1 and CP 2 for generating GBA defi-
ciency on demand in zebrafish, thus to create zebrafish models for 
neuropathic Gaucher, to assist research in the context of neuro-
pathic GD and PD. 
The Supporting Information is available free of charge on the ACS 
Publications website.  
Experimental data and procedures, crystallographic data and syn-
thesis (PDF). 
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